Last update May 11, 2019

Terazosin Hydrochloride

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

It is an alpha-1-adrenergic blocking agent that is used for treatment of arterial hypertension and of obstructive symptoms resulting from benign prostatic hypertrophy.
Oral administration once a day.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic characteristics (moderately elevated molecular weight and high plasma protein binding and large volume of distribution, make it very unlikely its excretion into breast milk in significant amounts and its subsequent absorption by the infant.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Anderson 2018, Malachias 2016, Schaefer 2007 p685), especially during the neonatal period and in case of prematurity

Alternatives

  • Doxazosin Mesylate ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Finasteride (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Labetalol Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Methyldopa ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoprolol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nifedipine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nimodipine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Propranolol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Tamsulosin (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Terazosin Hydrochloride is also known as


Terazosin Hydrochloride in other languages or writings:

Tradenames

Main tradenames from several countries containing Terazosin Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 460 daltons
Protein Binding 94 %
pKa 7.24 -
Tmax 1 - 2 hours
9 - 12 hours

References

  1. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  2. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  3. KPh. Terazosina. Ficha técnica. 2013 Full text (in our servers)
  4. Terazosin. Drug Summary. 2010 Full text (in our servers)
  5. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, second edition. London. 2007

Total visits

3,751

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM